Wells Fargo on Thursday raised its price target on Sarepta Therapeutics, Inc. (SRPT) to $50 from $48 after the company’s ...

SRPT rallies after Q2 earnings and revenue beat expectations as Elevidys deliveries resume following FDA clearance.

Vor Bio has handed Dallan Murray a swift return to the workforce. | Vor Bio has handed Dallan Murray a swift return to the ...

Sarepta did not hold an investor call for its second-quarter earnings report or provide an updated full-year revenue outlook.

Yet, within the past 24 hours, Trump has doubled the tariffs on India to 50%, imposed an additional 15% on Japan, announced a ...

THE LAWSUIT: A class action securities lawsuit was filed against Sarepta Therapeutics, Inc. that seeks to recover losses of shareholders who were adversely affected by alleged securities fraud between ...

National shareholders rights firm Hagens Berman continues to investigate the lawsuit's legal claims and urges Sarepta investors who suffered substantial losses to submit your losses now . The firm ...

After a second Elevidys patient death from acute liver failure, Sarepta in July launched a major restructuring that involves ...

Shares of Sarepta Therapeutics (NASDAQ:SRPT) rose on Wednesday after the market as it reported second quarter revenue and ...

Sarepta Therapeutics Inc. (SRPT) on Wednesday reported second-quarter net income of $196.9 million. On a per-share basis, the ...

CAMBRIDGE, Mass. - Sarepta Therapeutics, Inc. (NASDAQ: SRPT) shares jumped 3.7% after the precision genetic medicine company reported second-quarter earnings that significantly exceeded analyst ...